Open AccessAntihypertensive therapy in patients with liver diseases. Can we decrease the risk of liver fibrosis by affecting renin-angiotensin system?
Author(s) -
О. М. Драпкина,
Yu. V. Dubolazova
Publication year - 2009
Publication title -
arterialʹnaâ gipertenziâ
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.126
H-Index - 5
eISSN - 2411-8524
pISSN - 1607-419X
DOI - 10.18705/1607-419x-2009-15-5-529-531
Subject(s) - blockade , medicine , renin–angiotensin system , fibrosis , blood pressure , aldosterone , liver fibrosis , angiotensin ii , concomitant , inflammation , antihypertensive drug , pharmacology , cardiology , endocrinology , receptor
The paper summarizes data on antihypertensive treatment in hypertensive patients with concomitant hepatic diseases when inflammation and fibrosis result in liver cytoarchitecture changes. Rennin-angiotensin-aldosterone system blockade enables to reduce tissue damage and fibrosis development regardless of blood pressure decrease. The majority of hypertensive patients requiring combination antihypertensive therapy can benefit in achieving target blood pressure faster, decreasing side effects risk, and in improving liver function. Key words: hypertension, liver diseases, rennin-angiotensin-aldosterone system blockade.